Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2018 08:00 ET | Source: Dermira, Inc.

Dermira to Present at 17th Annual Needham Healthcare Conference

MENLO PARK, Calif., March 20, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 08, 2018 16:05 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 08, 2018 08:00 ET | Source: Dermira, Inc.

Dermira to Present at Cowen & Company 38th Annual Healthcare Conference

MENLO PARK, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
March 05, 2018 07:59 ET | Source: Dermira, Inc.

Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints

Company expects to discontinue the programConference call and webcast today at 8:30 a.m. ET / 5:30 a.m. PT MENLO PARK, Calif., March 05, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM),...
February 22, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update

Olumacostat glasaretil topline Phase 3 data expected Q1 2018FDA decision on glycopyrronium tosylate New Drug Application expected by June 30, 2018Lebrikizumab Phase 2b study enrolling patients and...
February 17, 2018 18:30 ET | Source: Dermira, Inc.

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new...
February 12, 2018 08:30 ET | Source: Dermira, Inc.

Dermira Showcases Commitment to Hyperhidrosis Education and Treatment at Leading Dermatology Conference

MENLO PARK, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
February 09, 2018 08:30 ET | Source: Dermira, Inc.

Dermira to Present at Leerink Partners 7th Annual Global Healthcare Conference

MENLO PARK, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
February 08, 2018 16:01 ET | Source: Dermira, Inc.

Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MENLO PARK, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
January 31, 2018 08:30 ET | Source: Dermira, Inc.

Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

Study expected to enroll approximately 275 patientsTopline results expected in the first half of 2019TREBLE Phase 2 proof-of-concept results published in the Journal of the American Academy of...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right